Blissel® offers women with vaginal atrophy a different treatment experience

This Valentine’s Day, a message that comes from the heart from the team at Consilient Health.

To help women give themselves treatment in a comfortable and mess-free way, Blissel® comes with an applicator.1

Blissel® is the first and only prescribable estriol containing gel for the treatment of vaginal atrophy.1.2

My BlisselⓇ Time to talk
Video Library

A library of discussions led by national experts Dr Anne Connolly, Dr Diana Mansour and Nurse Specialist Consultant Nikki Noble.
The videos cover a range of very useful, relevant and important topics, including How Blissel® works, the time until Blissel® takes effect, and how to use an applicator.

Click here to open and play the videos

Women need support and treatment guidance

Blissel® is formulated as a mucoadhesive gel, using specialist polycarbophylic ingredients, which leads to a moisturising effect, whilst also making sure that the active hormone is not lost.3

Products not formulated with mucoadhesive ingredients may end up being in contact with the vaginal tissue for a shorter time and may lead to leakage.3

The British Menopause Society advocates the lowest HRT dose that will effectively manage a patient’s symptoms should be prescribed for vaginal atrophy.4

Formulations that contain a low dose of estriol, such as Blissel, can lead to lower systemic absorption.5

With Blissel®, women may get rapid relief

Blissel® is well-tolerated and effective for postmenopausal vaginal atrophy, and can lead to rapid symptomatic improvement for your patient from the first days of treatment.2,3

Blissel® is an ultra low dose estriol vaginal gel containing 50 micrograms per dose (1 gram) of estriol, which is indicated for treating the symptoms of vaginal atrophy due to oestrogen deficiency in postmenopausal women.1,2

Click to watch our How to use the Blissel® applicator video

Upcoming Webinars 2025

Throughout 2025, we will be hosting a series of webinars focused on key topics in women’s health. These sessions are designed with a patient-centred approach, ensuring the latest evidence-based insights are shared. One of the topics we will explore is the clinical use of a prescribable estriol-containing gel for the management of vaginal atrophy, helping healthcare professionals identify patients who may benefit from this treatment.

Click Here To Find Out More

How BlisselⓇ
Works

Efficacy

Dosing

Ultra low dose estriol vaginal gel1,2

Prescribing and Adverse event reporting information for BlisselⓇ can be found here.

 Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com 

  1. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.
  2. Cano A, et al. Menopause. 2012;19(10):1130-9.
  3. Lázaro-Carrasco de la Fuente J, et al. J Menopausal Med. 2022;28(2):60-69.
  4. British Menopause Society Women’s Health Concern Fact Sheet: HRT Benefits and Risks; Nov 2022.
  5. Delgado JL, et al. Climacteric. 2016;19(2):172-80.

Date of preparation: Jan 2025 | UK-BLS-614